Report Detail

Request for Sample of this report

Other Global COVID-19 Inactivated Vaccine Market 2020 by Company, Regions, Type and Application, Forecast to 2025

  • RnM3960329
    • |
  • 01 May, 2020
    • |
  • Global
    • |
  • 127 Pages
    • |
  • GIR (Global Info Research)
    • |
  • Other

Market Overview
The COVID-19 Inactivated Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.


The most likely (base case) scenario is that the global COVID-19 Inactivated Vaccine sales will be xx in 2020 from COVID-19 Inactivated Vaccine million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global COVID-19 Inactivated Vaccine market size is expected to grow at xx% or more annually for the next five years.


This report also researches and evaluates the impact of Covid-19 outbreak on the COVID-19 Inactivated Vaccine industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on COVID-19 Inactivated Vaccine and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).


Market segmentation
COVID-19 Inactivated Vaccine market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.


By Type, COVID-19 Inactivated Vaccine market has been segmented into:
In Clinical Trials
Out-of-Clinical Trials


By Application, COVID-19 Inactivated Vaccine has been segmented into:
Hospital
Clinic
Other


Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global COVID-19 Inactivated Vaccine market presented in the report. This section sheds light on the sales growth of different regional and country-level COVID-19 Inactivated Vaccine markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global COVID-19 Inactivated Vaccine market.


The report offers in-depth assessment of the growth and other aspects of the COVID-19 Inactivated Vaccine market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)


Competitive Landscape and COVID-19 Inactivated Vaccine Market Share Analysis
COVID-19 Inactivated Vaccine competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, COVID-19 Inactivated Vaccine sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the COVID-19 Inactivated Vaccine sales, revenue and market share for each player covered in this report.


The major players covered in COVID-19 Inactivated Vaccine are:
Inovio Pharmaceuticals
Altimmune
Codagenix, Inc.
Takis Biotech (Evvivax)
Janssen Pharmaceutical Companies
Zydus Cadila
CanSino Biologics
Bravovax
GeoVax, Inc.
Vaxart
Generex
Baylor
ExpreS2ion Biotechnologies ApS
Moderna, Inc.
Novavax, Inc.
Vaxil Bio Ltd.
Clover Biopharmaceuticals
iBio, Inc.
Sanofi Pasteur
GSK
Curevac
ImmunoPrecise
Among other players domestic and global, COVID-19 Inactivated Vaccine market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.


1 COVID-19 Inactivated Vaccine Market Overview

  • 1.1 Product Overview and Scope of COVID-19 Inactivated Vaccine
  • 1.2 Classification of COVID-19 Inactivated Vaccine by Type
    • 1.2.1 Global COVID-19 Inactivated Vaccine Revenue by Type: 2015 VS 2019 VS 2025
    • 1.2.2 Global COVID-19 Inactivated Vaccine Revenue Market Share by Type in 2019
    • 1.2.3 In Clinical Trials
    • 1.2.4 Out-of-Clinical Trials
  • 1.3 Global COVID-19 Inactivated Vaccine Market by Application
    • 1.3.1 Overview: Global COVID-19 Inactivated Vaccine Revenue by Application: 2015 VS 2019 VS 2025
    • 1.3.2 Hospital
    • 1.3.3 Clinic
    • 1.3.4 Other
  • 1.4 Global COVID-19 Inactivated Vaccine Market by Regions
    • 1.4.1 Global COVID-19 Inactivated Vaccine Market Size by Regions: 2015 VS 2019 VS 2025
    • 1.4.2 Global Market Size of COVID-19 Inactivated Vaccine (2015-2025)
    • 1.4.3 North America (USA, Canada and Mexico) COVID-19 Inactivated Vaccine Status and Prospect (2015-2025)
    • 1.4.4 Europe (Germany, France, UK, Russia and Italy) COVID-19 Inactivated Vaccine Status and Prospect (2015-2025)
    • 1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) COVID-19 Inactivated Vaccine Status and Prospect (2015-2025)
    • 1.4.6 South America (Brazil, Argentina, Colombia) COVID-19 Inactivated Vaccine Status and Prospect (2015-2025)
    • 1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) COVID-19 Inactivated Vaccine Status and Prospect (2015-2025)
  • 1.5 COVID-19 Outbreak: COVID-19 Inactivated Vaccine Industry Impact
    • 1.5.1 COVID-19 Potential Implications for the COVID-19 Inactivated Vaccine
      • 1.5.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on COVID-19 Inactivated Vaccine
      • 1.5.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
      • 1.5.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
      • 1.5.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
    • 1.5.2 Opportunity Analysis in Covid-19 Crisis
    • 1.5.3 Market Risk and Restraints
    • 1.5.4 Market Driving Force

2 Company Profiles

  • 2.1 Inovio Pharmaceuticals
    • 2.1.1 Inovio Pharmaceuticals Details
    • 2.1.2 Inovio Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.1.3 Inovio Pharmaceuticals SWOT Analysis
    • 2.1.4 Inovio Pharmaceuticals Product and Services
    • 2.1.5 Inovio Pharmaceuticals COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.2 Altimmune
    • 2.2.1 Altimmune Details
    • 2.2.2 Altimmune Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.2.3 Altimmune SWOT Analysis
    • 2.2.4 Altimmune Product and Services
    • 2.2.5 Altimmune COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.3 Codagenix, Inc.
    • 2.3.1 Codagenix, Inc. Details
    • 2.3.2 Codagenix, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.3.3 Codagenix, Inc. SWOT Analysis
    • 2.3.4 Codagenix, Inc. Product and Services
    • 2.3.5 Codagenix, Inc. COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.4 Takis Biotech (Evvivax)
    • 2.4.1 Takis Biotech (Evvivax) Details
    • 2.4.2 Takis Biotech (Evvivax) Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.4.3 Takis Biotech (Evvivax) SWOT Analysis
    • 2.4.4 Takis Biotech (Evvivax) Product and Services
    • 2.4.5 Takis Biotech (Evvivax) COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.5 Janssen Pharmaceutical Companies
    • 2.5.1 Janssen Pharmaceutical Companies Details
    • 2.5.2 Janssen Pharmaceutical Companies Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.5.3 Janssen Pharmaceutical Companies SWOT Analysis
    • 2.5.4 Janssen Pharmaceutical Companies Product and Services
    • 2.5.5 Janssen Pharmaceutical Companies COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.6 Zydus Cadila
    • 2.6.1 Zydus Cadila Details
    • 2.6.2 Zydus Cadila Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.6.3 Zydus Cadila SWOT Analysis
    • 2.6.4 Zydus Cadila Product and Services
    • 2.6.5 Zydus Cadila COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.7 CanSino Biologics
    • 2.7.1 CanSino Biologics Details
    • 2.7.2 CanSino Biologics Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.7.3 CanSino Biologics SWOT Analysis
    • 2.7.4 CanSino Biologics Product and Services
    • 2.7.5 CanSino Biologics COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.8 Bravovax
    • 2.8.1 Bravovax Details
    • 2.8.2 Bravovax Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.8.3 Bravovax SWOT Analysis
    • 2.8.4 Bravovax Product and Services
    • 2.8.5 Bravovax COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.9 GeoVax, Inc.
    • 2.9.1 GeoVax, Inc. Details
    • 2.9.2 GeoVax, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.9.3 GeoVax, Inc. SWOT Analysis
    • 2.9.4 GeoVax, Inc. Product and Services
    • 2.9.5 GeoVax, Inc. COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.10 Vaxart
    • 2.10.1 Vaxart Details
    • 2.10.2 Vaxart Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.10.3 Vaxart SWOT Analysis
    • 2.10.4 Vaxart Product and Services
    • 2.10.5 Vaxart COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.11 Generex
    • 2.11.1 Generex Details
    • 2.11.2 Generex Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.11.3 Generex SWOT Analysis
    • 2.11.4 Generex Product and Services
    • 2.11.5 Generex COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.12 Baylor
    • 2.12.1 Baylor Details
    • 2.12.2 Baylor Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.12.3 Baylor SWOT Analysis
    • 2.12.4 Baylor Product and Services
    • 2.12.5 Baylor COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.13 ExpreS2ion Biotechnologies ApS
    • 2.13.1 ExpreS2ion Biotechnologies ApS Details
    • 2.13.2 ExpreS2ion Biotechnologies ApS Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.13.3 ExpreS2ion Biotechnologies ApS SWOT Analysis
    • 2.13.4 ExpreS2ion Biotechnologies ApS Product and Services
    • 2.13.5 ExpreS2ion Biotechnologies ApS COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.14 Moderna, Inc.
    • 2.14.1 Moderna, Inc. Details
    • 2.14.2 Moderna, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.14.3 Moderna, Inc. SWOT Analysis
    • 2.14.4 Moderna, Inc. Product and Services
    • 2.14.5 Moderna, Inc. COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.15 Novavax, Inc.
    • 2.15.1 Novavax, Inc. Details
    • 2.15.2 Novavax, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.15.3 Novavax, Inc. SWOT Analysis
    • 2.15.4 Novavax, Inc. Product and Services
    • 2.15.5 Novavax, Inc. COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.16 Vaxil Bio Ltd.
    • 2.16.1 Vaxil Bio Ltd. Details
    • 2.16.2 Vaxil Bio Ltd. Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.16.3 Vaxil Bio Ltd. SWOT Analysis
    • 2.16.4 Vaxil Bio Ltd. Product and Services
    • 2.16.5 Vaxil Bio Ltd. COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.17 Clover Biopharmaceuticals
    • 2.17.1 Clover Biopharmaceuticals Details
    • 2.17.2 Clover Biopharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.17.3 Clover Biopharmaceuticals SWOT Analysis
    • 2.17.4 Clover Biopharmaceuticals Product and Services
    • 2.17.5 Clover Biopharmaceuticals COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.18 iBio, Inc.
    • 2.18.1 iBio, Inc. Details
    • 2.18.2 iBio, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.18.3 iBio, Inc. SWOT Analysis
    • 2.18.4 iBio, Inc. Product and Services
    • 2.18.3 iBio, Inc. COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.19 Sanofi Pasteur
    • 2.19.1 Sanofi Pasteur Details
    • 2.19.2 Sanofi Pasteur Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.19.3 Sanofi Pasteur SWOT Analysis
    • 2.19.4 Sanofi Pasteur Product and Services
    • 2.19.5 Sanofi Pasteur COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.20 GSK
    • 2.20.1 GSK Details
    • 2.20.2 GSK Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.20.3 GSK SWOT Analysis
    • 2.20.4 GSK Product and Services
    • 2.20.5 GSK COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.21 Curevac
    • 2.21.1 Curevac Details
    • 2.21.2 Curevac Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.21.3 Curevac SWOT Analysis
    • 2.21.4 Curevac Product and Services
    • 2.21.5 Curevac COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)
  • 2.22 ImmunoPrecise
    • 2.22.1 ImmunoPrecise Details
    • 2.22.2 ImmunoPrecise Major Business and Total Revenue (Financial Highlights) Analysis
    • 2.22.3 ImmunoPrecise SWOT Analysis
    • 2.22.4 ImmunoPrecise Product and Services
    • 2.22.5 ImmunoPrecise COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2018-2019)

3 Market Competition, by Players

  • 3.1 Global COVID-19 Inactivated Vaccine Revenue and Share by Players (2015-2020)
  • 3.2 Market Concentration Rate
    • 3.2.1 Top 5 COVID-19 Inactivated Vaccine Players Market Share
    • 3.2.2 Top 10 COVID-19 Inactivated Vaccine Players Market Share
  • 3.3 Market Competition Trend

4 Market Size by Regions

  • 4.1 Global COVID-19 Inactivated Vaccine Revenue and Market Share by Regions
  • 4.2 North America COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
  • 4.3 Europe COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
  • 4.4 Asia-Pacific COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
  • 4.5 South America COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
  • 4.6 Middle East & Africa COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)

5 North America COVID-19 Inactivated Vaccine Revenue by Countries

  • 5.1 North America COVID-19 Inactivated Vaccine Revenue by Countries (2015-2020)
  • 5.2 USA COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
  • 5.3 Canada COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
  • 5.4 Mexico COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)

6 Europe COVID-19 Inactivated Vaccine Revenue by Countries

  • 6.1 Europe COVID-19 Inactivated Vaccine Revenue by Countries (2015-2020)
  • 6.2 Germany COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
  • 6.3 UK COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
  • 6.4 France COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
  • 6.5 Russia COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
  • 6.6 Italy COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)

7 Asia-Pacific COVID-19 Inactivated Vaccine Revenue by Countries

  • 7.1 Asia-Pacific COVID-19 Inactivated Vaccine Revenue by Countries (2015-2020)
  • 7.2 China COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
  • 7.3 Japan COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
  • 7.4 Korea COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
  • 7.5 India COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
  • 7.6 Southeast Asia COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)

8 South America COVID-19 Inactivated Vaccine Revenue by Countries

  • 8.1 South America COVID-19 Inactivated Vaccine Revenue by Countries (2015-2020)
  • 8.2 Brazil COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
  • 8.3 Argentina COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)

9 Middle East & Africa Revenue COVID-19 Inactivated Vaccine by Countries

  • 9.1 Middle East & Africa COVID-19 Inactivated Vaccine Revenue by Countries (2015-2020)
  • 9.2 Saudi Arabia COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
  • 9.3 UAE COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
  • 9.4 Egypt COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)
  • 9.5 South Africa COVID-19 Inactivated Vaccine Revenue and Growth Rate (2015-2020)

10 Market Size Segment by Type

  • 10.1 Global COVID-19 Inactivated Vaccine Revenue and Market Share by Type (2015-2020)
  • 10.2 Global COVID-19 Inactivated Vaccine Market Forecast by Type (2019-2024)
  • 10.3 In Clinical Trials Revenue Growth Rate (2015-2025)
  • 10.4 Out-of-Clinical Trials Revenue Growth Rate (2015-2025)

11 Global COVID-19 Inactivated Vaccine Market Segment by Application

  • 11.1 Global COVID-19 Inactivated Vaccine Revenue Market Share by Application (2015-2020)
  • 11.2 COVID-19 Inactivated Vaccine Market Forecast by Application (2019-2024)
  • 11.3 Hospital Revenue Growth (2015-2020)
  • 11.4 Clinic Revenue Growth (2015-2020)
  • 11.5 Other Revenue Growth (2015-2020)

12 Global COVID-19 Inactivated Vaccine Market Size Forecast (2021-2025)

  • 12.1 Global COVID-19 Inactivated Vaccine Market Size Forecast (2021-2025)
  • 12.2 Global COVID-19 Inactivated Vaccine Market Forecast by Regions (2021-2025)
  • 12.3 North America COVID-19 Inactivated Vaccine Revenue Market Forecast (2021-2025)
  • 12.4 Europe COVID-19 Inactivated Vaccine Revenue Market Forecast (2021-2025)
  • 12.5 Asia-Pacific COVID-19 Inactivated Vaccine Revenue Market Forecast (2021-2025)
  • 12.6 South America COVID-19 Inactivated Vaccine Revenue Market Forecast (2021-2025)
  • 12.7 Middle East & Africa COVID-19 Inactivated Vaccine Revenue Market Forecast (2021-2025)

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Data Source
    • 14.3 Disclaimer

    Summary:
    Get latest Market Research Reports on Inactivated Vaccine. Industry analysis & Market Report on Inactivated Vaccine is a syndicated market report, published as Global COVID-19 Inactivated Vaccine Market 2020 by Company, Regions, Type and Application, Forecast to 2025. It is complete Research Study and Industry Analysis of Inactivated Vaccine market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,500.00
    		$7,000.00
    		2,835.00
    		5,670.00
    		3,286.50
    		6,573.00
    		541,660.00
    		1,083,320.00
    		291,900.00
    		583,800.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo